Navigation Links
Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Date:9/8/2008

PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it received a milestone payment for an undisclosed amount from its licensing partner, Pfizer Inc. (NYSE: PFE). This payment is a result of the submission of an Investigational New Drug (IND) application by Pfizer for the clinical development of an antibody generated by Medarex's UltiMAb(R) technology. Medarex may receive future milestone payments and royalties should this product candidate progress through clinical development and to the market.

"We are pleased with the progress that Pfizer has made in advancing this antibody, generated using our UltiMAb(R) technology, towards the clinic," said Howard H. Pien, President and CEO of Medarex. "The continued development progress by Pfizer and our other partners reinforces the potential of products generated using our UltiMAb(R) antibody technology to treat life-threatening diseases."

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
2. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
3. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
4. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
5. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
6. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
7. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
8. Medarex Announces Ipilimumab Program Continues to Move Forward
9. Medarex to Receive Milestone Payment from Amgen
10. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
11. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Rock Creek Pharmaceuticals, ... it has initiated the development of its lead molecule, ... that it has selected Quotient Clinical, The Translational Pharmaceutics ... (UK) to run its early development programs. ... Application (CTA) by the end of the third quarter ...
(Date:7/31/2014)... Calif. , July 31, 2014 Lazarus ... of novel interventional devices to facilitate removal of blood ... Proceeds from the financing will support EU commercialization of ... filings for the Lazarus ReCover™ and Lazarus Cover™ in ... "This financing reflects investor confidence in the value of ...
(Date:7/31/2014)... and VIENNA , July 31, 2014 ... press conference in New York results ... vaccine against Parkinson,s disease. PD01A is the first therapy against ... clinical testing. The Michael J. Fox Foundation for ... million grant, and presented at the press conference on the ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
(Date:8/1/2014)... of electronic reminders such as text messages, emails or ... adhere to a preadmission antiseptic showering regimen known to ... to a first-of-its-kind study published in the August issue ... Surgeons . , Each year approximately 400,000 SSIs occur ... according to data sources cited by study authors. ...
(Date:8/1/2014)... CO (PRWEB) August 01, 2014 According to ... onto the Internet do so in search of information, and ... website, those in search of information and resources on insurance ... , “We're excited to take this next step in the ... DCInsurers Colorado Springs - Commercial Insurance Resources office. ...
(Date:8/1/2014)... Home Care Assistance of Cincinnati , a ... be recognized as a 2014 Best of Home Care Employer ... providers who rank in the top 50th percentile in one ... conducted by Home Care Pulse. , “The Best of ... best of the best!” says Home Care Pulse Founder and ...
(Date:8/1/2014)... Ticket Down is a reputable source for ... in Knoxville/Greenback, TN; Ingram Farms in Auburn/Opelika, AL; Cross Creek ... FL. Luke Bryan is currently out on his summer “That’s ... Swindell. Bryan is responsible for one of the most popular ... year, just because the summer is over doesn’t mean that ...
(Date:8/1/2014)... Researchers and doctors at the Institute of Bioengineering ... National Cancer Centre Singapore (NCCS) have co-developed the ... and survival outcomes in kidney cancer patients. This ... , the world,s top urology journal. , ... Ying, "By combining our expertise in molecular diagnostics ...
Breaking Medicine News(10 mins):Health News:Electronic reminders can help patients prevent surgical site infections 2Health News:Electronic reminders can help patients prevent surgical site infections 3Health News:DCInsurers Agent Doug King Launches a New Website 2Health News:DCInsurers Agent Doug King Launches a New Website 3Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 3Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 4Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3
... World Health Organization (WHO), is calling for renewed vigilance against ... Korea, Hong Kong, Indonesia and Vietnam have been reported. There’s ... was probably due to a mutated H5N1 virus that could ... pandemic is overdue and could happen during the winter months. ...
... come out with findings from a study that indicates ... celexa in combating// depression. ,Dr. Fran?ois Lespérance, ... colleagues published their findings in this week’s edition of ... ,The drug celexa, which goes by the generic name ...
... Bilcare, a leading research-based pharmaceutical packing solution ... with Honeywell//, a UK-based pharma packaging firm, ... pharmaceutical sector. ,"The partnership with Honeywell's ... provide state-of-the-art materials for ensuing safety of ...
... maternal DNA in the blood of around 20% of children ... also seemed to help in producing insulin, which is not ... to restore damaged tissue in the pancreas. They also found ... immune system. ,During pregnancy, stem cells of ...
... the high prevalence of HIV/AIDS in Karnataka and hoping to ... Kumaraswamy will spend Tuesday night in the hut of a ... in Bagalkot district, 600 km from the state capital Bangalore ... around 11 p.m. and spend the night in the house ...
... coffee could help cure baldness as caffeine blocks the effects ... ,Tobias Fischer of the University of Jena in Germany took ... hair loss. He extracted hair follicles and placed them in ... ,The samples were left in the laboratory for ...
Cached Medicine News:Health News:Are We Prepared for Flu Pandemic? 2Health News:Citalopram, a Boon in Treating Depressed Heart Patients 2Health News:Karnataka Chief Minister to Spend Night With HIV Positive Family 2
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Medicine Products: